Effects of α, β momorcharin extract of momordica charantia in intracellular free calcium on cancer cell lines.
DOI:
https://doi.org/10.31878/ijcrpp.2019.31.1Keywords:
α, β momorcharin, momordica charantia, cancer cell lineAbstract
The Momordica charantia L., (family: Cucurbitaceae) is a scientific name of the plant and its fruit. It is also known by other names, for instance in the USA it is known as Bitter gourd or balsam pear while its referred to as the African cucumber in many African countries. This study was specifically designed to investigate the cellular mechanisms whereby alpha, beta momorcharin an extract of M. charantiacan induce cell death measuring the elevation in intracellular free calcium concentrations in three different cancer cell lines 1321N1, Gos-3 and U-87. The results show that incubation of the three cancer cell lines 1321N1, Gos-3 and U-87 with α, β momorcharin can result in significant (p < 0.05) time-dependent increases in [Ca2+]i in all three cancer cell lines compared to control (untreated) cells. Maximal increases in [Ca2+]i was attained after 420 min of incubation.In control (untreated cell lines), [Ca2+]i remained more or less stable in both cell lines after 420 min. The results also show that the increase in [Ca2+]i in Gos-3 cell line was much more pronounced following incubation with α, β momorcharin compared to 1321N1 and U-87 cell line. The results show that incubation of the three cancer cell lines with momorcharin can result in significant (p < 0.05) time-dependent increases in [Ca2+]i in all three cancer cell lines compared to control (untreated) cells. Maximal increases in [Ca2+]i was attained after 420 min of incubation. In control (untreated cell lines), [Ca2+]i remained more or less stable in all three cell lines after 420 min. These results clearly show that α, β momorcharin extract of M. charantia is exerting its anti- cancer effect via an insult to the mitochondria resulting in apoptosis, calcium overloading and subsequently, cell death.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 GUNASEKAR MANOHARAN
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.